This is Lundbeck

We are one of the only biopharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About us

In Conversation: Thomas Gibbs, EVP and President

"What matters most is having products and pipelines that are truly differentiated and address real unmet needs, paired with strong people, leadership, and culture."

Beyond the pipeline: What it means to commit to innovation in neuro-rare 

As a Focused Innovator, we are building on our legacy in brain health to serve neuro-rare communities with bold science, clear strategy, and deep commitment to patients.

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our science

A better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person and community behind the disease.

Our focus

Our sustainability strategy

Through our sustainability strategy, we mitigate business risks, reduce negative impacts, and address societal challenges where possible. We remain committed to UN Global Compact Principles, and contribute to seven of the 17 UN Sustainable Development Goals.

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

Judy Krieg, Account Manager

Judy’s caregiving journey: Reflections after caring for parents with dementia and Alzheimer’s disease

See all stories

We are Lundbeck

In the U.S., we have approximately 1,000+ colleagues working tirelessly to advance neuroscience, deliver new and innovative treatments and support patient communities. 

Lundbeck in the U.S.